Monitoring response in lymphomas: qualitative, quantitative, or what else?

@article{Biggi2019MonitoringRI,
  title={Monitoring response in lymphomas: qualitative, quantitative, or what else?},
  author={Alberto Biggi and Fabrizio Bergesio and St{\'e}phane Chauvie},
  journal={Leukemia \& Lymphoma},
  year={2019},
  volume={60},
  pages={302 - 308}
}
Abstract The Deauville criteria (DC) shall always be used to report interim and final PET and to assign metabolic response categories in FDG-avid lymphoma. A recent review article supports the role of quantitative extension of the DC to improve response assessment in lymphoma. We analyze different quantitative approach, to help physician to better distinguish what has to be done in every day clinical practice respect to what represent interesting insights and ongoing research. Respect to DC… 
3 Citations
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial
Positron emission computed tomography (PET/CT) in patients with diffuse large B‐cell lymphoma (DLBCL) enrolled in a prospective clinical trial were reviewed to test the impact of quantitative
Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma
TLDR
The results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.
Agresif B hücreli Hodgkin dışı ve Hodgkin lenfomada ilk basamak tedavi yanıtının FDG-PET/BT ile değerlendirilmesinde rezidüel SUVmax
Bu calismada; lenfomada ilk basamak tedavi sonrasinda Flor-18 fluorodeoksiglukoz pozitron emisyon tomografisinin (FDG-PET/BT) reziduel SUV max degerine gore duyarlilik ve ozgunlugunun geriye donuk

References

SHOWING 1-10 OF 30 REFERENCES
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
TLDR
Quantitative methods to perform PET in standardized ways have also been developed which may further improve response assessment including a quantitative extension to the DC (qPET), which may have advantages in providing a continuous scale to refine the threshold for adequate/inadequate response in specific clinical situations or treatment optimization in trials.
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
TLDR
This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
TLDR
The 5-point score proposed at Deauville for reviewing interim PET scans in advanced Hodgkin lymphoma is accurate and reproducible enough to be accepted as a standard reporting criterion in clinical practice and for clinical trials.
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
TLDR
Although the Deauville criteria are valid for assessing the prognostic value of early PET/CT in DLBCL, computation of the ΔSUVmax leads to better performance and interobserver reproducibility, and should be preferred when a baseline scan is available.
qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma
TLDR
qPET methodology provides semi-automatic quantification for interim FDG-PET response in lymphoma extending ordinal Deauville scoring to a continuous scale without need for follow-up data.
Report on the First International Workshop on interim-PET scan in lymphoma
TLDR
The aim of the workshop was to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma, and to launch two or more international validation studies, in an attempt to validate these rules.
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
TLDR
The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.
When should FDG‐PET be used in the modern management of lymphoma?
TLDR
The role of FDG PET‐CT throughout the management course in patients with lymphoma is explored, with areas discussed that may limit the use ofPET‐CT imaging which clinicians should be familiar with to inform practice.
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
TLDR
Both the previous and these new guidelines specifically aim to achieve standardised uptake value harmonisation in multicentre settings.
Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma.
  • A. Biggi, F. Bergesio, +7 authors A. Gallamini
  • Medicine
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2017
TLDR
Combining semi-quantitative parameters with SUVPeak to a pure qualitative interpretation key with DS is possible to increase the positive predictive value of iPET and to identify with higher precision the patients subset with a very dismal prognosis, however, these retrospective findings should be confirmed prospectively in a larger patient cohort.
...
1
2
3
...